Totally implantable central venous access ports. Analysis of 700 cases

Barbetakis, Nikolaos; Asteriou, Christos; Kleontas, Athanassios; Tsilikas, Christodoulos

doi:10.1002/jso.21990

Cited by 66 publications

(67 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pneumothorax is associated with increased resource utilization and potential mortality. In the present study, the overall incidence of pneumothorax was 0.8% (1 patient), in accordance with previously reported rates of between 0.5 and 6% [13-15]. In addition, the overall complication rate was 14.5% (14 patients), consistent with that reported by several studies (range 2–14.4%) [16-19].…”

Section: Discussionsupporting

confidence: 93%

Usefulness of Totally Implantable Central Venous Access Devices in Elderly Patients: A Retrospective Study

Imaoka

Kuranishi²,

Ogawa³

2018

Ann Nutr Metab

View full text Add to dashboard Cite

Background/Aims: The need for totally implantable central venous access devices (TICVADs) has increased with increased opportunities in the use of chemotherapy and parenteral nutrition. This study aimed to determine the outcomes of TICVAD implantation and use in patients aged ≥85 years. Methods: Between January 2010 and August 2016, 117 patients underwent TICVAD implantation and their records were retrospectively reviewed. Results: Participants were divided into 2 groups (plus-85 and sub-85 groups). Fifty-five patients (47.0%) had solid organ cancer alone; 35 patients (29.9%) had cerebrovascular or cranial nerve disease. The average follow-up period was 201 (2–1,620) days. Major complications were identified in 6 (14.6%) plus-85 patients and 11 (14.5%) sub-85 patients (p = 0.9813). Catheter-related infections developed in 3 plus-85 (7.3%) and 4 sub-85 patients (5.3%; p = 0.6549). There were no significant group differences in hematoma, pneumothorax, occlusion, and removal rates. In plus-85 patients examined just before surgery and a month after surgery, increased rates of serum albumin and Onodera’s prognostic nutritional index were observed in 48% (14/39) and 41% (12/39), respectively. Conclusions: The use of TICVADs in the plus-85 group resulted in effective outcomes. The results of this retrospective study support the wider use of TICVADs in patients aged ≥85 years.

show abstract

Section: Discussionsupporting

confidence: 93%

Usefulness of Totally Implantable Central Venous Access Devices in Elderly Patients: A Retrospective Study

Imaoka

Kuranishi²,

Ogawa³

2018

Ann Nutr Metab

View full text Add to dashboard Cite

show abstract

“…TIVAP provides long-term central venous access and thus simplify the administration of chemotherapy and parenteral nutrition, as well as the repeated collection of blood samples [4]. Moreover, the TIVAP system has greatly improved the quality of life for patients with cancer, because it has enabled them to resume their normal daily activities while permitting a complete subcutaneous access [5]. Therefore, TIVAP has been considered as standard tools for management of cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Among these complications, TIVAP-related infection is the most common complication, occurring in 3-10 % cases, which frequently leads to TI-VAP removal [5,[9][10][11]. In patients with cancer, the risk of TIVAP-related infection seems to be stable over time with infection rates of 0.21 and 0.20 per 1,000 catheter days, respectively, in 1993 and 2011 [5,12].…”

Section: Introductionmentioning

confidence: 99%

Infections Related to Totally Implantable Venous-Access Ports: Long-Term Experience in One Center

Yang

Miao

et al. 2014

Cell Biochem Biophys

View full text Add to dashboard Cite

The purpose of this study was to investigate the incidence and risk factors of infections associated with totally implantable venous-access ports (TIVAPs) in our hospital. From April 2007 through November 2013, a total of 1,026 patients with TIVAP were included in this study. We retrospectively analyzed the incidence of port-related infection, patient characteristics, and history. Risk factors for IVAP-related infection were determined statistically. Overall, 97 (9.59 %) of 1,026 infectious cases were reported. By reviewing the medical record of the patients, we found that younger age, hematogenous malignancy, and palliative chemotherapy were associated with higher infection incidence rate in patients who had implanted TIVAP (P < 0.05) in the subgroup analysis. In contrast, gender and insertion site were irrelevant factors in predicting the infection risk. Overall, TIVAP were proved to be safe and effective. Younger age, hematogenous malignancy, and palliative chemotherapy were associated with higher infection in patients who had implanted TIVAP.

show abstract

“…Totally implantable venous access port (TIVAP)-related infections (RIs) represent a serious and persistent health problem in cancer patients with significantly increased morbidity and hospital costs [1,2] . In cancer patients, the TIVAP-RI risk is of 0.20‰ catheter-days [1][2][3] , coagulase-negative staphylococci being the most common cause [4] .…”

Section: Introductionmentioning

confidence: 99%

“…In cancer patients, the TIVAP-RI risk is of 0.20‰ catheter-days [1][2][3] , coagulase-negative staphylococci being the most common cause [4] . TIVAP-RIs are usually classified into 3 subtypes: (1) local site infections; (2) TIVAP-related bloodstream infections (BSI); and (3) catheter-related infections [5] .…”

Section: Introductionmentioning

confidence: 99%

Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV<b> </b>Trial (ATAPAC)

Longo¹,

Llorens

Goetz

et al. 2017

Oncology

View full text Add to dashboard Cite

Background: Totally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.) therapy. Patients and Methods: The ATAPAC study was a prospective, randomized, monocentric, phase IV trial evaluating the efficacy of taurolidine lock solution versus standard saline solution for primary TIVAP-RI prevention in nonhematological cancer patients receiving i.v. chemotherapy. The primary endpoint was the TIVAP-RI incidence rate. From December 2014 to September 2015, 163 patients were enrolled in the study (taurolidine: n = 86 vs. control: n = 77). Four patients in the control group (5%) had a Staphylococcus epidermidis TIVAP-RI, and 1 patient (1%) in the taurolidine group had a Staphylococcus aureus infection. The TIVAP-RI incidence rate was 0.4 and 0.1‰ catheter-days, respectively (p = 0.21). The infection-free TIVAP survival was not statistically significant (p = 0.09). TIVAP-RI required a total of 22 hospitalization days in the taurolidine group versus 106 days in the control arm with associated costs of EUR 4,849 and EUR 36,020, respectively. Taurolidine-related toxicity was transitory and classified as grade I. Conclusions: The ATAPAC trial did not show a significant risk-infection reduction by TauroLock™. A larger, prospective, randomized trial is needed to assess TauroLock efficacy for primary TIVAP-RI prevention in low-risk cancer patients.

show abstract

Totally implantable central venous access ports. Analysis of 700 cases

Abstract: The low rate of complications according to this study confirms the safety and convenience of the percutaneous insertion and use of TICVAP in patients undergoing prolonged chemotherapy regimens and explains the increasing use of these devices in current medical oncology practice.

Cited by 66 publications

References 8 publications

Usefulness of Totally Implantable Central Venous Access Devices in Elderly Patients: A Retrospective Study

Usefulness of Totally Implantable Central Venous Access Devices in Elderly Patients: A Retrospective Study

Infections Related to Totally Implantable Venous-Access Ports: Long-Term Experience in One Center

Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV<b> </b>Trial (ATAPAC)

Contact Info

Product

Resources

About